Bliss GVS Pharma (BLISSGVS-BE) Share Price Falls 5% Today to Rs 686.35

Bliss GVS Pharma Share Price fell to Rs 686.35 on 15 September 2026, down 5% from the previous close of Rs 722.45, taking the company’s market capitalisation to Rs 7,681.84 crore. The Mid Cap pharmaceutical stock is drawing attention because the day’s decline was sharp enough to stand out, even though the broader supplied data does not establish any company-specific catalyst for the move.

For investors tracking Bliss GVS Pharma Share Price Today, the session matters for three reasons. First, the stock opened lower at Rs 698.10 and moved down to its intraday low of Rs 686.35 after touching a day high of Rs 722. Second, the turnover stood at Rs 0.61 crore, confirming active price discovery around the decline. Third, the stock still sits above its 50-day moving average of Rs 583.93 and 200-day moving average of Rs 379.64, while its core valuation and profitability ratios place it in an interesting position within the Healthcare and Pharmaceuticals & Drugs space. On Univest, that combination makes this one of the more notable stock updates in today’s market news.

Bliss GVS Pharma (BLISSGVS-BE) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 686.35
Previous Close	Rs 722.45
Today's Move	-Rs 36.10 (-5%)
Open	Rs 698.1
High	Rs 722
Low	Rs 686.35
Turnover	Rs 0.61 crore
Market Capitalisation	Rs 7,681.84 crore
Market Cap Category	Mid Cap

Bliss GVS Pharma Share Price Today reflects a clear same-day decline, with the stock falling Rs 36.10 from Rs 722.45 to Rs 686.35, a move of -5%. The session began at Rs 698.10, which already placed the stock below the previous close, and the day high of Rs 722 shows it briefly tested levels near the prior settlement before weakening. The day low of Rs 686.35 also matches the current traded price in the supplied data, indicating the stock was at the lower end of its intraday range at the time of this update.

Turnover of Rs 0.61 crore suggests the price move drew market participation even as the stock eased. For a Mid Cap name with a market cap of Rs 7,681.84 crore, that makes the day’s price action relevant for traders watching near-term levels and investors tracking Bliss GVS Pharma Share News. Importantly, the supplied data confirms the share price decline but does not establish a company-specific reason for why Bliss GVS Pharma Stock Falling Today. That shifts attention from headline speculation to how the stock is positioned on valuation, profitability and broader industry comparison.

Bliss GVS Pharma (BLISSGVS-BE) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 7,681.84 crore
P/E Ratio	56.41x
P/B Ratio	6.23x
ROE	12.11%
ROCE	17.4%
EPS	Rs 12.81
Book Value Per Share	Rs 115.94
Dividend Yield	0.21%

Bliss GVS Pharma Fundamental Analysis shows a company valued at Rs 7,681.84 crore with a price-to-earnings ratio of 56.41 and a price-to-book ratio of 6.23. EPS stands at Rs 12.81, which represents earnings attributable to each share, while book value per share is Rs 115.94, indicating the accounting net worth behind each share. The dividend yield is 0.21, which points to a relatively modest historical payout relative to the current stock price.

From a profitability angle, return on equity is 12.11% and return on capital employed is 17.4%. Those figures indicate the business is generating returns above double digits, with ROCE stronger than ROE. The valuation multiples, however, show that the market is assigning a richer earnings and book-value multiple to the stock than many companies typically trade at in this industry. That does not automatically make the stock overvalued or undervalued, but it does mean the Bliss GVS Pharma Share Price is being judged against a relatively demanding set of expectations. For readers following Bliss GVS Pharma Financial Results and Bliss GVS Pharma Earnings, the balance between valuation and operating returns is central to the present stock analysis on Univest.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	56.41x
Benchmark Median P/E	32.72x
Benchmark Average P/E	49.15x
Benchmark P/E Range	3.34x to 693.7x
Company P/B Ratio	6.23x
Benchmark Median P/B	3.05x
Benchmark Average P/B	4.37x
Company ROE	12.11%
Benchmark Median ROE	11.69%
Benchmark Average ROE	10.54%
Company ROCE	17.4%
Benchmark Median ROCE	13.24%
Benchmark Average ROCE	13.09%
Company Market Capitalisation	Rs 7,681.84 crore
Benchmark Median Market Cap	Rs 704.59 crore
Benchmark Average Market Cap	Rs 13,873.11 crore

The sector benchmark places the stock in Healthcare, specifically the Pharmaceuticals & Drugs industry, and that context is important because it shows where Bliss GVS Pharma sits relative to 204 same-industry companies. In this benchmark set, the company’s P/E of 56.41 is above the industry median of 32.72 and also above the average of 49.15. The broader P/E range is wide, from 3.34 to 693.7 across 169 companies, so the stock is not an outlier at the extreme end, but it is clearly trading above the middle of the industry pack.

The same pattern appears in price-to-book. Bliss GVS Pharma trades at 6.23 times book value, above the industry median of 3.05 and the average of 4.37, across 203 companies. On profitability, the picture is steadier. Its ROE of 12.11% is slightly above the industry median of 11.69% and above the average of 10.54. ROCE of 17.4% is also ahead of the median of 13.24% and average of 13.09. In market-cap terms, Bliss GVS Pharma at Rs 7,681.84 crore is well above the industry median of Rs 704.59 crore, though below the average of Rs 13,873.11 crore in a sector where the range runs from Rs 3.8 crore to Rs 4,41,957.5 crore. For investors reading Bliss GVS Pharma Stock News, the takeaway is a stock with above-benchmark valuation and better-than-benchmark operating return ratios.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Sun Pharmaceutical Industries	SUNPHARMA	4,41,957.5	36.54	5.11	14.85	19.11
Divi's Laboratories	DIVISLAB	2,47,576	84.64	14.02	16.19	21.51
Torrent Pharmaceuticals	TORNTPHARM	1,89,233.01	86.76	21.08	26.76	19.27
Zydus Lifesciences	ZYDUSLIFE	1,11,670.55	24.74	4.14	19.69	21.39
Cipla	CIPLA	1,10,272.68	32.72	3.14	11.83	16

Peer comparison shows Bliss GVS Pharma operating in a far smaller size bracket than major listed pharmaceutical companies, but its valuation and return profile still invite direct comparison. Against Sun Pharmaceutical Industries, Cipla and Zydus Lifesciences, Bliss GVS Pharma carries a higher P/E than Sun Pharma’s 36.54, Cipla’s 32.72 and Zydus Lifesciences’ 24.74. It is lower than Divi’s Laboratories at 84.64 and Torrent Pharmaceuticals at 86.76. That places the stock in the upper valuation half of this peer set.

On profitability, Bliss GVS Pharma’s ROE of 12.11% is above Cipla’s 11.83 and Aurobindo Pharma’s 9.93 in the wider benchmark list, but below Sun Pharma’s 14.85, Divi’s 16.19, Zydus Lifesciences’ 19.69 and Torrent Pharmaceuticals’ 26.76. Its ROCE of 17.4% is stronger than Cipla’s 16.00, but trails Sun Pharma’s 19.11, Divi’s 21.51, Zydus Lifesciences’ 21.39 and Torrent’s 19.27. The market-cap gap is even more pronounced, with Bliss GVS Pharma at Rs 7,681.84 crore versus peers running from Rs 1,10,272.68 crore for Cipla to Rs 4,41,957.5 crore for Sun Pharma. On Univest, that makes Bliss GVS Pharma Share Price a case of a smaller pharma company trading on relatively full multiples compared with several much larger peers.

Why Investors Are Watching Bliss GVS Pharma

• Sharp daily move: the stock declined 5% to Rs 686.35, down Rs 36.10 from Rs 722.45.
• Intraday weakness: it opened at Rs 698.10, touched Rs 722 and slipped to a low of Rs 686.35.
• Rich valuation: the P/E of 56.41 and P/B of 6.23 are above industry median levels.
• Profitability support: ROE of 12.11% and ROCE of 17.4% are above sector median benchmarks.
• Trend context: the stock remains above its 50 DMA of Rs 583.93 and 200 DMA of Rs 379.64.

About Bliss GVS Pharma

Bliss GVS Pharma operates in the Healthcare sector and is part of the Pharmaceuticals & Drugs industry. Based on the supplied classification, the company sits in the listed pharma universe where investors often compare stocks on earnings multiples, return ratios and market capitalisation. With a market cap of Rs 7,681.84 crore, it is meaningfully larger than the industry median company size of Rs 704.59 crore, though much smaller than the biggest established pharmaceutical players in the benchmark group. That positioning helps explain why Bliss GVS Pharma Latest News and Bliss GVS Pharma Company News attract interest when the share price shows notable intraday movement.

Track Bliss GVS Pharma Share Price on Univest

UseUnivest top decliners screener,Univest market blogsto review live stock data, top decliners and related market analysis.

On Univest, users can track Bliss GVS Pharma Share Price Live alongside key market data points such as daily price action, market capitalisation, valuation ratios, moving averages, 52-week levels and sector comparisons. Univest also helps investors follow Bliss GVS Pharma Stock Analysis through profitability metrics like ROE, ROCE, EPS, book value and dividend yield, making it easier to place a single-day move in broader context without jumping to unsupported conclusions.

Frequently Asked Questions

Why did Bliss GVS Pharma Share Price fall today?

Ans. Bliss GVS Pharma Share Price fell 5% to Rs 686.35 from the previous close of Rs 722.45. The supplied data confirms the decline and intraday weakness, but it does not establish any company-specific catalyst behind today’s move.

What is Bliss GVS Pharma Share Price Today?

Ans. Bliss GVS Pharma Share Price Today is Rs 686.35 as of the supplied update. The stock was down Rs 36.10 or 5%, after opening at Rs 698.10 and moving within an intraday range of Rs 686.35 to Rs 722.

What does today’s price action show for Bliss GVS Pharma?

Ans. Today’s price action shows a weak session. The stock opened below the previous close, briefly reached Rs 722, and then slipped to Rs 686.35, which was also the day’s low at the time of the update.

Is Bliss GVS Pharma a Mid Cap stock?

Ans. Yes, Bliss GVS Pharma is classified as a Mid Cap stock in the supplied data. Its market capitalisation stands at Rs 7,681.84 crore, placing it above the industry median company size of Rs 704.59 crore.

How is Bliss GVS Pharma valued compared with its industry?

Ans. Bliss GVS Pharma trades at a P/E of 56.41, above the same-industry median of 32.72 and average of 49.15. Its P/B of 6.23 is also above the industry median of 3.05 and average of 4.37.

What do Bliss GVS Pharma profitability ratios indicate?

Ans. The company’s ROE is 12.11% and ROCE is 17.4%. Both are above the Pharmaceuticals & Drugs industry median levels of 11.69% and 13.24%, indicating profitability metrics that are stronger than the benchmark midpoint.

What are the key per-share metrics for Bliss GVS Pharma?

Ans. Bliss GVS Pharma reports EPS of Rs 12.81, book value of Rs 115.94 per share and dividend yield of 0.21. These figures help investors assess earnings support, net worth backing and the stock’s historical payout profile.

How does Bliss GVS Pharma compare with major pharma peers?

Ans. Bliss GVS Pharma is much smaller by market cap than peers such as Sun Pharma, Cipla, Zydus Lifesciences, Divi’s and Torrent Pharmaceuticals. Its P/E is higher than Sun, Cipla and Zydus, but lower than Divi’s and Torrent.

What should investors monitor next in Bliss GVS Pharma Stock News?

Ans. Investors should monitor whether Bliss GVS Pharma Share Price stabilises after falling to Rs 686.35, and whether valuation at 56.41 times earnings continues to align with ROE of 12.11% and ROCE of 17.4%.